Thrombocytopenia is a condition characterized by a lower-than-normal platelet count, increasing risk of bruising and bleeding. Causes include decreased production, increased destruction, splenic sequestration, medications, infections, and systemic disease.
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
Telix said Part 1 of the ProstACT Global Phase 3 study met its primary objectives for TLX591-Tx in mCRPC. The company reported acceptable safety, no new safety signals and progression plans for Part 2.
Ruxolitinib remains the standard frontline therapy for intermediate-2 and high-risk myelofibrosis, with phase 3 and real-world data showing spleen and symptom benefits. Cytopenias, transfusion needs and resistance after 2 to 3 years continue to drive interest in new combinations.
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07442513 |
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT |
RECRUITING | PHASE3 |
| NCT07441720 |
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) |
RECRUITING | PHASE2 |
| NCT07257809 |
Herombopag Treated T-DM1 Induced Platelet Reduction |
RECRUITING | PHASE2 |
| NCT07185893 |
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors |
NOT_YET_RECRUITING | NA |
| NCT07122232 |
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria |
COMPLETED | |
| NCT07110090 |
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT) |
RECRUITING | PHASE1 |
| NCT07108023 |
Hematological Disorders in EHPVO Patients |
NOT_YET_RECRUITING | |
| NCT07025512 |
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia |
WITHDRAWN | PHASE2 |
| NCT06913374 |
The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT06886516 |
Apixaban in Thrombocytopenia |
RECRUITING | EARLY_PHASE1 |
